All blog posts
Total 91 results for
Showing 12 out of 91 results
09 11月 2026
China’s proposed technology export controls amendments: key takeaways for life sciences companies
14 10月 2026
Commission closes Sanofi disparagement case with commitments
26 8月 2026
Pharma M&A is back - H1 2026 Update
14 7月 2026
The EU Commission's new draft merger guidelines - key takeaways for pharma companies
16 6月 2026
2026 sees China's biotech scene continuing its ascent – but could US developments mean clouds on the horizon?
27 4月 2026
The EU Pharma Package is finally here – here's the settled position on key areas
12 3月 2026
Snapshot: Key European pharma regulatory, IP and competition developments from 2025 for the pharmaceutical sector
15 12月 2025
A new era for EU pharmaceutical law: political agreement reached on the reform
09 12月 2025
Preserving the status quo: Boehringer Ingelheim awarded interim injunction
15 10月 2025
Venture investment in life sciences – Activity update & outlook (US & Europe)
24 9月 2025
Biopharma M&A activity – strategics continue to lead the way
28 8月 2025
The Thursday Investment Club: The case for later living
Showing 12 out of 91 results
View moreKey contacts
Laura Orlando
Managing Partner, Milan Office, Milan
Alan Montgomery
Partner, Head of Life Sciences Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Life Sciences Sector, London